Beeline Medicines
Beeline Medicines develops clinical-stage therapies that target immune dysfunction in lupus and other autoimmune and inflammatory diseases.
$126.3MSeries A extension
ParticipantBC
Bain Capital
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 0 First participation on record · 1 follow-on
- Funding in participating rounds
- $126.3M 1 disclosed · full round size, not this investor’s share